Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71.